简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
Jiangxi Biology
JIANGXI BIOLOGY(06915.HK): Veterinary Tetanus Antitoxin Production Line Officially Put into Operation
Tags:
Jiangxi Biology
06915.HK
2026-07-27
JIANGXI BIOLOGY(06915.HK): Stabilisation Period Concludes, Over-Allotment Option Lapses
Tags:
Jiangxi Biology
06915.HK
2026-07-27
Jiangxi Biotech (06915.HK)Slumps 14.29% on Listing Day, Quoted at HK$9.60
Tags:
Jiangxi Biology
06915.HK
ListingDebut
IPO
2026-06-30
JIANGXI BIOLOGY(06915.HK) Launches Public Offering Today, Entry Fee Approximately HK$6,595.86
Tags:
Jiangxi Biology
06915.HK
IPO
public offering
2026-06-22
Jiangxi Biology Passes HKEX Hearing, World’s Largest Provider of Human Tetanus Antitoxin
Tags:
Jiangxi Biology
IPO
pass the listing hearing
2026-06-08
Featured News
Finance
JIANGXI BIOLOGY(06915.HK): Veterinary Tetanus Antitoxin Production Line Officially Put into Operation
Finance
Anker Innovations (00668.HK): H-shares Included in Stock Connect Eligible Securities List
Finance
IMPACT Therapeutics(07630.HK): IMP3201 Nominated as Preclinical Candidate Compound, a Dual-Loaded ADC Targeting CEACAM5
Finance
JIANGXI BIOLOGY(06915.HK): Stabilisation Period Concludes, Over-Allotment Option Lapses
Finance
UBTECH Robotics (09880.HK): Purchase of Shares from the Market Pursuant to H-share Incentive Scheme
Finance
Akeso(09926.HK): Grant of Share Options and Restricted Share Units
Finance
Home Control (01747.HK): Signs Strategic Cooperation MOU with Articura on Indonesia Localized Healthcare AI
Finance
Jacobio Pharmaceuticals(01167.HK): First Patient Dosed in Phase IIa Clinical Trial of BET Inhibitor JAB-8263 for Rheumatoid Arthritis
Finance
Fosun Pharma (02196.HK): DM1001 Preparation Obtains Clinical Trial Approval
Finance
China Financial Services(00605.HK): Grants RMB 8.9 Million Loan to Client
Scan QR Code
Download App